The central problem the researchers set out to address is deceptively simple to state but notoriously difficult to study. When nanoparticles enter the bloodstream, the reticuloendothelial system, a network of macrophage-rich organs dominated by the liver and spleen, recognizes them as foreign material and clears them within minutes to hours. A nanoparticle that is removed from circulation before it can reach a tumor delivers little drug to the disease and much to healthy tissue, compounding toxicity while blunting efficacy. Both PEGylation and red blood cell membrane coating are designed to defeat this clearance, but they do so through entirely different chemistry. PEG is a hydrophilic synthetic polymer that forms a hydration shell around particles, sterically blocking the adsorption of opsonins, the blood proteins that flag foreign material for destruction. Red blood cell membranes, by contrast, carry native ‘self’ markers, most famously the CD47 protein, which engages an inhibitory receptor on macrophages and delivers a molecular ‘don’t eat me’ signal. Yet despite the popularity of both approaches, the field has lacked rigorous head-to-head comparisons in which the only variable is the coating itself.

That gap is precisely what the Fujian team, led by Han Lin, Xiaoqin Wang, and corresponding author Qing Hu, set out to close. Their experimental design hinged on a single, identical nanocarrier core: albumin nanoparticles loaded with doxorubicin, a widely used chemotherapy agent. Albumin has become an attractive scaffold for drug delivery because it is biocompatible, biodegradable, and has a natural affinity for tumors, which scavenger albumin as a nutrient source. Building on this shared platform, the researchers constructed three formulations that differed only in their outermost surface. The first was the bare doxorubicin-loaded albumin nanoparticle, designated DOX-BSA, serving as the unmodified control. The second, DOX-BSA@LPs, was cloaked in PEGylated liposomes, representing the synthetic stealth strategy. The third, DOX-BSA@RMs, was camouflaged with red blood cell membranes, representing the biomimetic strategy. Because all three shared the same core, the same drug payload, and the same underlying particle, any differences in biological behavior could be attributed to the coating rather than to confounding variations in size, charge, or drug loading.

The team then subjected all three formulations to a systematic evaluation spanning physicochemical characterization, cellular behavior, tumor accumulation, and therapeutic performance. The physicochemical work confirmed that the coatings had been successfully applied and that the formulations were suitable for comparison, while the biological assays probed the questions that matter most for nanomedicine: how readily tumor cells take the particles up, how deeply the particles penetrate into tumor-like tissue, how much drug actually accumulates in tumors relative to healthy organs, and ultimately how well the treatments shrink tumors in living animals.

The first headline result was that both stealth strategies clearly worked. Compared with the unmodified DOX-BSA nanoparticles, both the PEGylated liposome-coated and the red blood cell membrane-coated versions showed significantly enhanced tumor accumulation and significantly improved anti-tumor efficacy, with the differences reaching statistical significance at the P < 0.05 threshold. This confirms, on a controlled albumin platform, the core premise of stealth nanotechnology: disguising the surface of a nanocarrier allows it to evade immune clearance long enough to reach its target. For a field in which many comparisons are confounded by differences in particle design, this clean demonstration of the stealth effect itself is a valuable benchmark.

But the more provocative finding lay in the comparison between the two coatings. Across multiple endpoints, the red blood cell membrane formulation, DOX-BSA@RMs, showed marginal yet statistically significant advantages over its PEGylated counterpart, DOX-BSA@LPs. In three-dimensional tumor spheroids, laboratory models that mimic the dense, poorly vascularized architecture of real tumors, the membrane-camouflaged particles penetrated deeper than the PEGylated ones. Penetration depth is a critical variable in solid tumor therapy because chemotherapeutics must reach not just the cells at the tumor periphery but the inner mass, where hypoxic and quiescent cells often survive treatment and seed relapse. A coating that improves access to the tumor interior could therefore translate into more complete tumor kill.

Histological examination of treated tumors reinforced the pattern. Tumors from animals treated with the red blood cell membrane formulation displayed more extensive necrosis and apoptosis, the two hallmarks of effective chemotherapy response, than tumors treated with the PEGylated formulation. Consistent with this, the membrane-coated particles achieved a higher tumor inhibition rate overall, meaning they shrank tumors more effectively in vivo. The researchers also measured tumor-to-normal-tissue ratios, a pharmacokinetic metric that captures how selectively a formulation homes in on tumors versus healthy organs, and found the ratios were superior for the membrane-camouflaged particles, indicating higher tumor accumulation relative to off-target deposition. Higher selectivity is the holy grail of chemotherapy, since it promises greater efficacy with fewer of the dose-limiting side effects, such as cardiotoxicity, that plague conventional doxorubicin.

Why might a biological membrane outperform a synthetic polymer, even if only by a modest margin? The authors’ findings are consistent with mechanistic ideas that have been accumulating in the literature. PEG, despite its success in products such as the liposomal doxorubicin formulation Doxil, the first FDA-approved nano-drug, is not without liabilities. Anti-PEG antibodies exist in a substantial fraction of the population, likely owing to widespread exposure to PEG-containing products, and recent work has shown that such antibodies can become enriched in the protein corona that forms around PEGylated nanocarriers, potentially accelerating clearance and altering cellular uptake on repeated dosing. Red blood cell membranes, by contrast, present a native repertoire of self-markers, including CD47, whose role as a ‘marker of self’ on erythrocytes was established in landmark work published in Science in 2000. In addition, membrane coatings preserve the mechanical deformability that allows red blood cells to squeeze through narrow capillaries, a property that some studies suggest may aid circulation and tissue penetration in ways that rigid synthetic coatings cannot replicate.

The significance of the study lies as much in its methodology as in its results. By fixing the core and varying only the coating, the researchers established what they describe as a comparative paradigm for evaluating nano-coatings, one that removes the confounders that have made it difficult to judge competing stealth strategies on their merits. Previous reviews of the field, including a 2024 analysis of stealth coatings in cancer models published in ACS Applied Materials and Interfaces, have noted that direct comparisons under uniform conditions are rare, leaving formulators to choose between PEGylation and membrane coating largely on the basis of precedent rather than evidence. The Fujian study provides that evidence for the albumin-doxorubicin system, and its framework can be readily applied to other payloads and other coating chemistries, from macrophage membranes to platelet membranes to hybrid coatings that combine features of several cell types.

Caveats remain, as they always do in preclinical nanomedicine. The advantages of the red blood cell membrane coating, while statistically significant, were described by the authors as marginal in magnitude, and the study evaluated a single drug, a single core material, and a single tumor model. Red blood cell membrane coatings also raise practical questions about sourcing, standardization, and scale-up that synthetic polymers do not, and the long-term immunological behavior of membrane-cloaked particles in repeat-dose regimens will require further study. Nevertheless, the work marks an important step toward rational, evidence-based design of nanocarrier surfaces. As cancer nanomedicine matures from proof-of-concept demonstrations toward optimized clinical formulations, studies that isolate the contribution of each design choice, rather than changing everything at once, are exactly what the field needs. On the evidence assembled by the Fujian Medical University team, when it comes to hiding a nanoparticle from the immune system long enough to deliver a lethal payload to a tumor, nature’s own disguise appears to hold a slight but real edge over the best synthetic imitation.

Subject of Research: Comparison of PEGylation and red blood cell membrane stealth coatings on doxorubicin-loaded albumin nanoparticles for antitumor drug delivery

Article Title: Comparison of PEGylation versus red blood cell membrane camouflage strategies: in vivo and in vitro antitumor efficacy of doxorubicin-loaded albumin nanoparticles

Article References: Lin, H., Wang, X., Lin, Z., Dai, T., Qiu, X., Yu, X., Yu, Y., & Hu, Q. (2026). Comparison of PEGylation versus red blood cell membrane camouflage strategies: in vivo and in vitro antitumor efficacy of doxorubicin-loaded albumin nanoparticles. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-026-00831-4

Image Credits: AI Generated

DOI: 10.1007/s40005-026-00831-4

Keywords: nanoparticles, drug delivery, PEGylation, red blood cell membrane, doxorubicin, albumin nanoparticles, stealth coating, tumor accumulation, cancer therapy, nanomedicine, biomimetic coating, CD47

Graphitic carbon nitride, often abbreviated as g-C3N4, is a two-dimensional polymeric material composed of carbon and nitrogen arranged in heptazine or triazine ring structures. It has attracted intense interest in photocatalysis because it absorbs visible light, is chemically robust, and contains no heavy metals. In biomedical contexts, these properties matter enormously: nanoparticles that persist in the body must not leach toxic ions, and materials activated by light in the visible or near-infrared range can be triggered from outside the body with spatial precision. What has limited clinical translation, however, is that bare carbon nitride particles are recognized and cleared by the immune system, aggregate in physiological salt concentrations, and lack any built-in affinity for the diseased tissues they are meant to treat.

The new study addresses these shortcomings by wrapping the nanoparticles in natural cell membranes, a strategy known as biomimetic coating. By cloaking graphitic carbon nitride nanoparticles in membranes derived from cells, the researchers effectively gave the particles a biological disguise. The membrane coating preserves the surface markers and proteins that cells use to communicate with their surroundings, allowing the nanoparticles to evade rapid immune clearance, navigate the complex protein milieu of blood, and preferentially accumulate at target sites such as tumors or inflamed tissue. This approach borrows directly from the way pathogens and circulating tumor cells disguise themselves to survive in the bloodstream, turning a survival trick of biology into an engineering tool.

The phrase multiscale photomodulation in the study’s title captures the platform’s defining feature. At the molecular scale, photoexcitation of graphitic carbon nitride generates electron-hole pairs that can drive the production of reactive oxygen species, the chemical basis of photodynamic therapy. At the cellular scale, these reactive species can damage cancer cell membranes, mitochondria, and DNA, triggering cell death pathways. At the tissue and organ scales, the particles’ light absorption and conversion properties can be harnessed for imaging, for localized heating through photothermal effects, and for modulating biological processes such as inflammation or neuronal activity. A single nanomaterial, the authors argue, can therefore serve as an optical actuator operating simultaneously at the molecular, cellular, and organismal levels.

Photodynamic therapy, one of the central applications, relies on photosensitizers that, upon light activation, transfer energy to ground-state oxygen to produce singlet oxygen and other cytotoxic reactive species. Conventional photosensitizers frequently suffer from poor water solubility, insufficient tissue penetration of the activating light, and off-target toxicity when illuminated light reaches healthy tissue. Graphitic carbon nitride nanoparticles offer an alternative photosensitizer with strong photocatalytic activity under visible light, high photostability that resists photobleaching, and a metal-free composition that simplifies regulatory and toxicity considerations. The biomimetic coating adds a layer of targeting that improves the therapeutic window by concentrating the photosensitizer where it is needed.

The therapeutic breadth described in the work extends beyond tumor ablation. Because light can be applied, removed, or tuned in real time, the platform functions as a programmable intervention: clinicians could in principle control the dose of reactive oxygen species or heat delivered to a lesion by adjusting illumination intensity, wavelength, and duration. The researchers describe applications in antimicrobial treatment, where photoinduced reactive species can kill drug-resistant bacteria without contributing to antibiotic resistance, and in immune modulation, where controlled photochemistry at the surface of membrane-coated particles can influence inflammatory signaling. Such versatility is rare in a single nanoplatform and reflects the underlying tunability of the semiconductor’s electronic structure.

A key technical achievement highlighted in the study is the stability of the membrane-nanoparticle hybrid in physiological conditions. Bare nanoscale semiconductors tend to aggregate in serum because proteins and salts screen electrostatic repulsion between particles. The biomimetic coating, by presenting a hydrated, biologically familiar surface, suppresses aggregation and prolongs circulation time. The coating also changes biodistribution: instead of being trapped rapidly by the liver and spleen, the disguised particles can circulate longer and exploit biological homing mechanisms, such as the affinity of tumor-cell membranes for their parent tumor tissue, to reach disease sites more efficiently. This homologous targeting principle has emerged in recent years as one of the most promising strategies in nanomedicine.

The work also speaks to a broader shift in how researchers think about the interface between synthetic materials and living systems. Rather than attempting to out-engineer biology with ever more exotic synthetic chemistries, the biomimetic approach integrates biological components directly into the material’s architecture. In this case, the rigid, optically active semiconductor core supplies the physical function, light harvesting and energy conversion, while the soft biological shell supplies the systemic function, immune evasion and targeting. The division of labor between core and shell illustrates a design philosophy that could extend to other two-dimensional materials, including transition-metal dichalcogenides and black phosphorus, which face similar barriers to biomedical use.

Safety remains a central question for any nanomaterial intended for clinical use, and the metal-free nature of graphitic carbon nitride is a meaningful advantage. Materials such as quantum dots containing cadmium or lead raise persistent concerns about long-term accumulation and ion release, whereas carbon nitride degrades into comparatively benign carbon- and nitrogen-containing species. The authors emphasize that biodegradability and clearance must still be rigorously characterized in advanced animal models and, eventually, in clinical trials, but the composition of the material removes an entire class of toxicity concerns at the outset.

The study’s authors position the platform as a foundation rather than a finished product. Future work, they suggest, could pair the particles with complementary light sources such as implantable LEDs or upconversion systems that shift near-infrared light into wavelengths the material absorbs more efficiently, extending treatment depth beyond the millimeter scale of conventional photodynamic therapy. Combining the photomodulation platform with immunotherapy, gene delivery, or responsive drug release could yield closed-loop systems in which light both diagnoses and treats. As biomimetic nanomaterials continue to mature, graphitic carbon nitride nanoparticles that speak the language of biology while harnessing the power of light may prove to be one of the more durable bridges between materials science and medicine.

Subject of Research: Biomimetic graphitic carbon nitride nanoparticles for multiscale photomodulation and light-activated therapeutic intervention

Article Title: Biomimetic graphitic carbon nitride nanoparticles for multiscale photomodulation and therapeutic intervention

Article References: Müller, C. A., Klompmaker, K. K., Zhang, Y., Zhang, J., Kalatanova, A., Li, P., Meng, L., Madsen, J. G., Jakobsen, T. S., Jørgensen, A. C., Askou, A. L., Luo, Y., Lin, L., Vogt Bleshøy, S., Bolis, G., Huang, G., Li, W., Davidsen, R. S., Bek, T., … Chen, M. (2026). Biomimetic graphitic carbon nitride nanoparticles for multiscale photomodulation and therapeutic intervention. Nature Biomedical Engineering. https://doi.org/10.1038/s41551-026-01773-w

Image Credits: AI Generated

DOI: 10.1038/s41551-026-01773-w

Keywords: graphitic carbon nitride, nanoparticles, biomimetic coating, photodynamic therapy, photomodulation, nanomedicine, reactive oxygen species, drug delivery, photothermal therapy, cell membrane coating, biodegradable nanomaterials, light-activated therapy